Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$536.87 USD
+5.01 (0.94%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $536.96 +0.09 (0.02%) 7:30 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$536.87 USD
+5.01 (0.94%)
Updated Jul 10, 2024 04:00 PM ET
After-Market: $536.96 +0.09 (0.02%) 7:30 PM ET
2-Buy of 5 2
C Value C Growth A Momentum B VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
What's in Store for Zimmer Biomet (ZBH) This Earnings Season?
by Zacks Equity Research
Focusing on areas like quality correction, supply recovery and product introductions, Zimmer Biomet (ZBH) is expected to see robust top-line numbers at S.E.T. arm in Q3.
Can Overall Growth Drive Thermo Fisher (TMO) Q3 Earnings?
by Zacks Equity Research
Thermo Fisher's (TMO) steadily strong analytical instrument business flaunts higher global demand.
Pacific Biosciences Introduces Enhancements to Sequel System
by Zacks Equity Research
The latest enhancements in Pacific Biosciences??? (PACB) Sequel System represent strong improvement in terms of read length, throughput and accuracy in DNA sequencing.
Will Edwards' (EW) Steady Overall Growth Drive Q3 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q3.
Can Overall Growth Drive Align Technology (ALGN) Q3 Earnings?
by Zacks Equity Research
Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q3.
Will 5 Elements Drive Quest Diagnostics (DGX) Q3 Earnings?
by Zacks Equity Research
Quest Diagnostics' (DGX) growing partnerships with health care leaders and strategic acquisitions are expected to boost top and bottom-line growth in Q3.
Thermo Fisher Scientific (TMO) Q3 Earnings Preview: What to Watch Ahead of the Release
by Zacks Equity Research
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Solid Overall Growth Drive Illumina (ILMN) Q3 Earnings?
by Zacks Equity Research
Illumina (ILMN) is likely to gain from strong revenues at the Product, Service and other segments in Q3.
Why Thermo Fisher (TMO) Could Beat Earnings Estimates Again
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Molecular Diagnostic Market Gains Momentum: 3 Stocks in Focus
by Sweta Jaiswal
Rising incidence of infectious diseases and increasing acceptance of companion diagnostics are driving the molecular diagnostics market.
Thermo Fisher (TMO) Scales a 52-Week High: What's Driving It?
by Zacks Equity Research
Thermo Fisher (TMO) sees strength in all end markets, categorized either by customer type or geography.
The Zacks Analyst Blog Highlights: Chevron, Amgen, Thermo Fisher, Estee Lauder and Delta Air Lines
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Amgen, Thermo Fisher, Estee Lauder and Delta Air Lines
Thermo Fisher (TMO) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Thermo Fisher (TMO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Stock Reports for Chevron, Amgen & Thermo Fisher
by Mark Vickery
Today's Research Daily features new research reports on 12 major stocks, including Chevron (CVX), Amgen (AMGN), and Thermo Fisher (TMO).
Here's Why You Should Hold on to Roper (ROP) Stock for Now
by Zacks Equity Research
Roper (ROP) stands to gain from acquired assets, healthy segmental business and operations in various markets. However, rising costs and buyout-related integration risks remain issues.
Stock Market News For Sep 10, 2018
by Zacks Equity Research
Markets ended sharply lower on Friday after President Donald Trump said that the United States was ready to move ahead with tariffs.
Thermo Fisher to Acquire BD's Advanced Bioprocessing Unit
by Zacks Equity Research
BD's (BDX) Advanced Bioprocessing business generates revenues worth $100 million annually. The unit will be integrated in the Thermo Fisher's (TMO) Life Sciences Solutions Segment.
Thermo Fisher (TMO) Up 0.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the company? We take a look at earnings estimates for some clues.
Pacific Biosciences' Sequel Sees Solid Q2, Competition Rife
by Zacks Equity Research
Pacific Biosciences (PACB) gains from solid presence in Asia; competition likely to mar results.
Allscripts (MDRX) Q2 Earnings In Line, Revenues Top Estimates
by Zacks Equity Research
Allscripts (MDRX) gains from solid segmental performance in Q2; a decline in bookings discourages.
Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM
by Zacks Equity Research
Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM
CONMED (CNMD) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
CONMED (CNMD) sees solid domestic and international sales in Q2; raised guidance encourages.
Masimo (MASI) Beats on Q2 Earnings, Raises 2018 Guidance
by Zacks Equity Research
Masimo (MASI) gains from solid segmental performance in Q2; non-invasive technology continues to be in demand.
Becton, Dickinson (BDX) Earnings and Revenues Beat in Q3
by Zacks Equity Research
Becton, Dickinson (BDX) gains from solid segmental and geographical sales in Q3.
5 Cheap PEG Stocks Suitable for GARP Investors
by Zacks Equity Research
Although PEG is categorized under value investing, this strategy follows the principles of both growth and value investing.